Abstract
Since Boron Neutron Capture Therapy is to be used in the treatment of primary and metastatic brain tumors, it is essential that the boron compounds be capable of crossing the blood-brain barrier (BBB) prior to their incorporation into tumor cells. It has been shown1 that derivatives of L-phenylalanine are transported across the BBB by neutral amino acid transport system. Recently, a method has been developed to deliver low molecular weight peptides into brain.2 These observations suggest that boronated analogues of phenylalanine itself and their peptides modified by replacing aromatic amino acids with highly lipophilic, carborane-containing amino acids might be used to reach and become incorporated into brain tumor cells protected by BBB.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G.J. Goldenberg, H.-Y.P. Lam and A. Begleiter. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J. Biol. Chem. 254: 1057 1064, 1979.
N. Bodor, L. Prokai, W.-M. Wu, H. Farag, S. Jonalagadda, M. Kawamura and J. Simpkins, A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 257: 1698–1670; 1992.
I.M. Wyzlic, A.H. Soloway, A general, convenient way to carborane-containing amino acids for boron neutron capture therapy. Tetrahedron Letters 33: 7489–7490; 1992.
J. Coderre, unpublished results.
J.L. Fauchere, K.Q. Do, P.Y.C. Jow and C. Hansch, Unusually strong lipophilicity of “fat” or “super” amino-acids, including a new reference value for glycine. Erperientia 36: 1203–1204, 1980.
P. Lindstrom, A. Gogoli, P. Rousell and S. Sjoberg, Self-degradation of ocarboranylalanine to the corresponding diastereomeric nido-analogues in acidic milieu. BUSA IF-Workshop on Boron Chemistry, Syracuse, July 1994.
W. Fischli, O. Leukart and R. Schwyzer, Hormone-receptor interactions. Carboranylalanine (Car) as a phenylalanine analogue: reactions with chymotrypsin. Hely. Chin. Acta 60: 959 963, 1977.
A. Eberle, O. Leukart, P. Schiller, J.-L. Fauchere and R. Schwyzer, Hormone-receptor interactions: [4-carboranylalanine, 5-leucine]enkephalin as a structural probe for the opiate receptor. FEBS Letters 82: 325–328, 1977.
E. Escher, G. Guillemette, O. Leucart and D. Regoli, Pharmacological properties of two analogues of angiotensin II containing carboranylalanine (Car). Eur: J. Pharmacol. 66: 267–272, 1980.
R. Couture, J.-N. Drouin, O. Leucart and D. Regoli, Biological activities of kinins and substance P (4–11) in which phenylalanine residues have been replaced with L-carboranylalanine. Can. J. Phvsiol. Pharnacol. 57: 1437–1442, 1979.
a) M. Node, K. Nishide, M. Sai, K. Fuji and E. Fugita, Hard acid and soft nucliophile systems. 3. dealkylation of esters with aluminum halide-sulfide systems. J. Oro. Chem. 46:1991–1993, 1981, b) T. Tsuji, T. Kataoka, M. Yoshioka, Y. Sendo, Y. Nishitani, S. Hirai, T. Maeda and W. Nagata, Synthetic studies on b-lactam antibiotics. VII. Mild removal of the benzyl ester protecting group with aluminum trichloride. Tetrahedron Letters 30: 2793–2796, 1979.
T.W. Greene, and G.M. Wuts, “Protective Groups in Organic Synthesis, 2nd edition” John Wiley and Sons, Inc., New York, 1991, pp. 449–452.
All new compounds were characterized by 1H NMR, i’C NMR and MS. Reported yields are for homogenous samples.
H. R. Kricheldorf and M. Fehrle, Uber einfuhrung and abspaltung der 2- nitrophenylsulfenylschutzgruppe bei aminosauren and oligiopeptiden. Srnthesi.s 422–424, 1974.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wyzlic, I.M., Beeson, J.C., Soloway, A.H., Yong, J., Barth, R.F. (1996). New Unnatural Boron-Containing Amino Acids and Peptides as Potential Delivery Agents for Neutron Capture Therapy. In: Mishima, Y. (eds) Cancer Neutron Capture Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9567-7_12
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9567-7_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9569-1
Online ISBN: 978-1-4757-9567-7
eBook Packages: Springer Book Archive